Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-10
DOI
10.3389/fneur.2021.805334
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
- (2021) J. Talbot et al. JOURNAL OF HEADACHE AND PAIN
- Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
- (2021) Konstantina Drellia et al. CEPHALALGIA
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada
- (2021) Marzieh Eghtesadi et al. CLINICAL DRUG INVESTIGATION
- MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
- (2021) Robert Belvís et al. JOURNAL OF HEADACHE AND PAIN
- Predictors of response to erenumab after 12 months of treatment
- (2021) Carlo Baraldi et al. Brain and Behavior
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- De Novo Visual Aura Onset in a Migraineur on Galcanezumab‐Gnlm
- (2020) Elizabeth Kearney et al. HEADACHE
- Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta‐analysis
- (2020) Raeburn B. Forbes et al. HEADACHE
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Predicting erenumab adverse events with single-cell genomics
- (2020) Angeliki Vgontzas et al. LANCET
- Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
- (2020) J. Schoenen et al. REVUE NEUROLOGIQUE
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
- (2020) Ashley Alex et al. HEADACHE
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications
- (2019) David W Dodick CEPHALALGIA
- Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials
- (2019) Da Xu et al. CEPHALALGIA
- Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece
- (2019) Theodoros V. Giannouchos et al. CLINICAL DRUG INVESTIGATION
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
- (2019) Bianca Raffaelli et al. JOURNAL OF HEADACHE AND PAIN
- Proposed new diagnostic criteria for chronic migraine
- (2019) Mona Ameri Chalmer et al. CEPHALALGIA
- Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood–brain barrier
- (2019) Agustin Melo-Carrillo et al. PAIN
- Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
- (2018) Cristina Tassorelli et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed
- (2018) Pamela Vo et al. CEPHALALGIA
- Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
- (2018) Dawn C Buse et al. CEPHALALGIA
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
- (2018) Janet H Ford et al. Patient Preference and Adherence
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Migraine and its psychiatric comorbidities
- (2016) Mia Tova Minen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example
- (2015) David W. Dodick et al. JOURNAL OF PAIN
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More